What’s the impact of a potential national pharmacare program on private drug plans?
Attendees heard the range of perspectives at the recent Face to Face Drug Plan Management Forum. The annual conference included a panel discussion about pharmacare, as well as sessions on hot topics in drug plans, such as drug price reform and pooling costs. The conference, which took place on Dec. 14 at the Fairmont Royal York Hotel, also presented an updated forecast of drug plan costs over the next five years.
Photos from the event are available in our photo gallery.
Here are the highlights of the sessions:
A look at the five-year forecast for drug plan cost increases
Employers will see private drug plan costs rise by about six per cent annually over the next five years, according to a prediction by a health-care research company.
Read more
The great pharmacare debate: An ‘overly simplistic’ solution or needed system rationalization?
Universal pharmacare is an “overly simplistic” solution that risks cutting access to drugs, says a senior executive at one of Canada’s largest pharmaceutical companies.
Read more
Options for getting the best value from drug plan spending
Employers should review their drug plans annually to make sure they’re getting value for money, according to a speaker at the recent Face to Face Drug Plan Management forum.
Read more
From biosimilars to PLAs: Panel addresses hot topics in drug plan management
From biosimilars to product listing agreements, a panel of experts tackled some of the hottest topics in drug plan management at the Face to Face Drug Plan Management forum on Dec. 14.
Read more
Deeper dive into cost projections nets big savings for benefits plan
With many of its plan members based in Alberta, the manager of Mercon Benefits Services was hoping to stay ahead of longer-term issues resulting from a turbulent provincial economy when she decided to take a deeper dive into projected benefits costs in 2015.
Read more